Doug Ingram to retire as Sarepta exits turbulent Duchenne era
Sarepta Therapeutics said CEO Doug Ingram will retire by year-end after a decade in which he steered the company to three Duchenne drug approvals and a peak value around $15 billion, followed by a downturn as safety concerns around its gene therapy and the rise of superior rivals weighed on the stock; Ingram cited family health reasons—his wife and son were diagnosed with myotonic dystrophy—and Sarepta is searching for a successor.